How does a biosimilar product obtain market approval under the BPCIA pathway?

• A. It must demonstrate biosimilarity to an approved reference product and obtain licensure under 351(k)
• B. It must prove chemical equivalence to a small-molecule drug
• C. It requires no clinical data
• D. It is approved by a special fast-track committee

Answer: (B)

The focal idea is how a biosimilar gains approval under the BPCIA pathway: it is licensed through the 351(k) abbreviated pathway by demonstrating biosimilarity to an already approved reference biologic. This means the sponsor must show that the biosimilar is highly similar to the reference product and that there are no clinically meaningful differences in safety, purity, or potency. Because biologics are large, complex molecules produced in living systems, they can never be exactly identical to the reference; instead, regulators assess the totality of evidence—comprehensive analytical comparisons of structure and function, followed by nonclinical and, when needed, clinical data—to confirm biosimilarity.

This differs from small-molecule generics, where chemical equivalence to a reference product is sufficient and the pathway relies on an abbreviated process under ANDA. The other statements don’t fit because a biosimilar uses the 351(k) pathway and does involve clinical data to support similarity; there is no separate fast-track committee for biosimilars.